Abstract:

Objective To observe the clinical efficacy of endostar combined with cisplatin in the treatment of malignant hydrothorax and ascites.Methods Endostar combined with cisplatin(combined group)was applied in 42 cases of patients with malignant hydrothorax and ascites.40 cases of patients with malignant hydrothorax and ascites treated by cisplatin(control team).Following a maxnium release of hydrothorax and ascites,endostar and cisplatin or cisplatin were injected,to evaluate recent efficacy and toxicity.Results Among 42 cases(combined group),there were 18 cases achieved CR,20 cases of PR,objective efficiency rate was 90.4 %.Among 40 cases(control group),39 cases of patients were found to improve their quality of life(92.9%),control group was 75%,there was significant differences between two groups(P=0.018).36 cases of patients with the increased level of VEGF,decrease of ≥25% of the baseline had a significantly better response rate and QOL improvement rate than patients with a decrease of ＜25%(P=0.027,P=0.006).In two groups,the occurrence rates of G3/4 toxicities were mainly beacause of cisplatin,including nausea,vomiting and fatigue,there was no significant differences of them.Conclusion Endostar combined with cisplatin can better control the malignant hydrothorax and ascites,clinical safety is better,it is worthy of clinical application.

Key words: Endostar, Cisplatin, Antiangiogenesis, Malignant hydrothorax, Malignant ascites